CA-ASM-GLOBAL
The Hong Kong Special Administrative Region Government, ASM Global and Kai Tak Sports Park Limited (KTSPL) — which is a subsidiary of New World Development — as part of a multiyear strategy, have announced a late winter testing period for Kai Tak marking the culmination of a near decade-long record $4 billion project creating the premiere sports, recreation, entertainment complex on Earth.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240417546819/en/
PLAY BALL – Kai Tak Sports Park, the largest and most ambitious sports-development and entertainment district in the world, is being managed by ASM Global. (Photo: Business Wire)
ASM Global, as the lead operator, has been on the ground in Hong Kong working for over five years supporting the design, programming and construction of Kai Tak Sports Park, featuring many of the world’s most advanced state-of-the-art venues and is now prepping for pre-opening activities in advance of 2025’s formal unveiling.
The project will include a 50,000-capacity main stadium with the theme “Pearl of the Orient” as its design inspiration and boasting a retractable roof and flexible pitch surface that can host a wide range of events in any weather, including major sports events, concerts and MICE events; a 10,000-capacity indoor sports arena that meets the standard of major international tournaments for a wide range of athletics, including basketball, tennis, gymnastics, family shows and other entertainment events; a 5,000-spectator, open-to-the-public sports ground for hosting school sports days, athletic meets, local football and rugby matches as well as team and athlete training sessions; and an outdoor recreation complex.
ASM Global’s President and CEO Ron Bension said, “ASM Global develops and builds spectacular venues and extraordinary entertainment districts throughout the world; but nothing compares to the scale, scope and state-of-the art innovation of Kai Tak.”
The Hong Kong site is part of ASM Global’s network of more than 400 venues around the world. The company works with major cultural and entertainment districts and venues and projects throughout the world, including Darling Harbour in Sydney, OVO Arena Wembley in London, AO Arena in Manchester and Desert Diamond in Arizona.
Officials said the expansive development will set the benchmark for multipurpose sports precincts worldwide, integrating the most advanced sports facilities with retail, wellness and community leisure spaces to create an urban oasis for the 7.4 million local community and millions of overseas visitors.
KTSPL, when awarded the contract for the design, build, construction and operation of the Kai Tak Sports Park, subsequently assembled an unparalleled project team comprising overseas and local experts in design; retail sales and marketing; construction led by Hip Hing; and ASM Global for project management, premium sales and programming.
The precinct is designed around the one-of-a-kind Kai Tak Sports Avenue. This indoor and outdoor pedestrian walk starts at Station Square and transports people completely through the immense site.
Throughout the complex will be restaurants, retail shops, jogging trails, a health and wellness center, as well as an international-standard bowling center with 40 lanes suitable for hosting international tournaments and a climbing wall on Sports Avenue.
ASM Global and KTSPL’s state-of-the-art environmentally conscious design decisions are critical to the project, intended to set and meet measurable goals to reduce impacts on the planet and champion dynamic programs for the longevity and well-being of the local community.
The focus of these sustainability efforts includes integration of photovoltaic panels on all major facilities, extensive green roofscapes and an expansive network of electric charging stations across the precinct. Smart city initiatives include an intelligent building and car management system, Wi-Fi hotspots, an indoor positioning system and mobile applications to facilitate precinct information booking of facilities and wayfinding.
Kai Tak Sports Park is expected to formally open in early 2025 and is one of the sports venues that will deliver events for the 2025 15th National Games of China that is being hosted in the Greater Bay Area.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240417546819/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Axelspace: Notice of Signing a Service contract for In-Orbit Demonstration with Pale Blue, Inc.22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” has entered into a service agreement with Pale Blue Inc. (“Pale Blue”), a company that develops, manufactures, and sells thrusters (engines) for small satellites, for an in-orbit demonstration, as detailed below. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219321165/en/ Jun Asakawa, Co-founder & CEO of Pale Blue (left in photo) and Yuya Nakamura, President and CEO of Axelspace Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Under this contract, an in-orbit demonstration of a fast-start Hall thruster developed by Pale Blue is scheduled to be conducted in 2027. Nonetheless, conducting in-orbit demonstrations in a short period of time is known to be a significant challenge due to the in
Axelspace Signing Agreement on a Multi-Launch Arrangement and the Launch of New Satellites with Exolaunch22.12.2025 10:00:00 CET | Press release
Axelspace Corporation (“Axelspace”), a leading microsatellite company committed to making “Space within Your Reach,” is pleased to announce a multi-launch agreement (MLA) with Exolaunch, a global launch integrator and leader in launch mission management, satellite integration and satellite deployment technologies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251219038364/en/ The Multi-Launch Agreement will accelerate the growth of Axelspace. In particular, one satellite scheduled for launch under the new Agreement will be used in the AxelLiner business’s in-orbit demonstration service, “AxelLiner Laboratory”. Exolaunch has already secured launches for eight (8) Axelspace’s satellites on the upcoming missions. Axelspace provides AxelLiner Laboratory (AL Lab), a new service originating from the AxelLiner business that is specialized in in-orbit demonstration of space components. Nonetheless, conducting in-orbit demonstration
Zambon Biotech Announces First Patient Dosed in Phase 3b ADIP Clinical Study of IPX203 in Parkinson’s Disease22.12.2025 10:00:00 CET | Press release
Zambon Biotech, a specialized biotech company part of the Zambon group that aims to build a scientifically robust and commercially viable portfolio of innovative patient-oriented drugs through the scouting, acquisition, licensing and development of new molecules, today announced that the first participant with advanced Parkinson’s disease has been enrolled in the European Phase 3b ADIP (IPX203 in Advanced Parkinson’s disease) study, which is planned to evaluate the efficacy and safety of IPX203 versus immediate-release (IR) levodopa/carbidopa (LD/CD) in a regimen which has not yet been the focus of a Phase 3 trial. IPX203 is a novel, oral modified-release formulation of LD/CD designed for the treatment of Parkinson’s disease, the fastest growing neurological condition in the world according to the World Health Organization1. IPX203 contains immediate-release granules and extended-release beads, providing both a rapid onset of action and a longer duration of benefit, sustaining the levo
Pimicotinib Approved as Systemic Treatment in China for Tenosynovial Giant Cell Tumor22.12.2025 09:00:00 CET | Press release
First regulatory approval in the world for pimicotinib based on positive data from global Phase 3 MANEUVER studyIn MANEUVER, pimicotinib significantly improved objective response rate at week 25 (54% vs. 3.2% for placebo), while providing clinically meaningful and statistically significant improvements across all patient-reported outcomesWith longer-term follow-up, 3 out of 4 patients treated with pimicotinib achieved response per RECIST v1.1, and treatment continued to be well-toleratedApproval strengthens Merck’s leadership in rare tumors, with additional ongoing regulatory filings for pimicotinib underway globally Merck, a leading science and technology company, announced today that following Priority Review, the China National Medical Products Administration (NMPA) has approved pimicotinib for the treatment of adult patients with symptomatic tenosynovial giant cell tumor (TGCT) for which surgical resection will potentially cause functional limitation or relatively severe morbidity.
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Rituximab and Lenalidomide for the Treatment of Relapsed or Refractory Follicular Lymphoma22.12.2025 08:44:00 CET | Press release
Incyte Biosciences Japan G.K. today announced approval from Japan's Ministry of Health, Labour and Welfare (MHLW) for Minjuvi® (tafasitamab) in combination with rituximab and lenalidomide for adult patients with relapsed or refractory follicular lymphoma (2L+ FL). “Today's approval of Minjuvi in combination with rituximab and lenalidomide marks a significant milestone as the first dual-targeted CD19 and CD20 immunotherapy combination for relapsed or refractory FL in Japan,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “By improving progression-free survival, Minjuvi offers a chemotherapy-free option for eligible patients with relapsed or refractory disease. This approval underscores our commitment to bridging critical treatment gaps to patients and families affected by this challenging disease in Japan.” The approval is based on the pivotal Phase 3 inMIND trial, which enrolled 654 adult patients, including patients based in Japan. The study demonstrated that Minjuvi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom